1.05 USD
-0.02 (-1.87%)
Overall MBIO gets a fundamental rating of 3 out of 10. We evaluated MBIO against 525 industry peers in the Biotechnology industry. The financial health of MBIO is average, but there are quite some concerns on its profitability. MBIO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year MBIO has reported negative net income.
- In the past year MBIO has reported a negative cash flow from operations.
- MBIO had negative earnings in each of the past 5 years.
- In the past 5 years MBIO always reported negative operating cash flow.
1.2 Ratios
- MBIO has a Return On Assets of -12.06%. This is amongst the best in the industry. MBIO outperforms 82.67% of its industry peers.
- Looking at the Return On Equity, with a value of -23.90%, MBIO belongs to the top of the industry, outperforming 80.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.06% | ||
| ROE | -23.9% | ||
| ROIC | N/A |
ROA(3y)-182.96%
ROA(5y)-131.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for MBIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- MBIO has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for MBIO has been reduced compared to 5 years ago.
- MBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -27.98, we must say that MBIO is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -27.98, MBIO is doing worse than 86.10% of the companies in the same industry.
- There is no outstanding debt for MBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -27.98 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 2.05 indicates that MBIO has no problem at all paying its short term obligations.
- MBIO's Current ratio of 2.05 is on the low side compared to the rest of the industry. MBIO is outperformed by 75.43% of its industry peers.
- MBIO has a Quick Ratio of 2.05. This indicates that MBIO is financially healthy and has no problem in meeting its short term obligations.
- MBIO has a worse Quick ratio (2.05) than 73.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.05 | ||
| Quick Ratio | 2.05 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 98.53% over the past year.
EPS 1Y (TTM)98.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 15.53% on average over the next years. This is quite good.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.62%
EPS Next 2Y39.11%
EPS Next 3Y25.28%
EPS Next 5Y15.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- MBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year MBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- MBIO's earnings are expected to grow with 25.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.11%
EPS Next 3Y25.28%
5. Dividend
5.1 Amount
- No dividends for MBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MUSTANG BIO INC / MBIO FAQ
What is the ChartMill fundamental rating of MUSTANG BIO INC (MBIO) stock?
ChartMill assigns a fundamental rating of 3 / 10 to MBIO.
Can you provide the valuation status for MUSTANG BIO INC?
ChartMill assigns a valuation rating of 1 / 10 to MUSTANG BIO INC (MBIO). This can be considered as Overvalued.
Can you provide the profitability details for MUSTANG BIO INC?
MUSTANG BIO INC (MBIO) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for MBIO stock?
The Earnings per Share (EPS) of MUSTANG BIO INC (MBIO) is expected to grow by 42.62% in the next year.